Biotech

The Company brings the health benefits of its flagship product VINIA(R) to the United States Market.

BioHarvest Sciences Inc. (CSE: BHSC) (FSE: 8MV) ("BioHarvest" or the "Company") announces the launch of direct-to-consumer sales of its flagship product VINIA® in the United States, via its vinia.com website.

After years of developing its BioFarming technology, the company is proud to bring the first product based on this technology to the US market. VINIA® is the first and only product in the world containing Piceid Resveratrol from red grapes at levels in each 400mg capsule of VINIA® equivalent to an average bottle of red wine, providing the benefits of red wine with the advantage of zero calories, zero sugar and zero percent alcohol. The Piceid Resveratrol contained in VINIA® has the unique ability to be solubilized in the body and is 25 times more soluble than resveratrol from polygonum, which is used today across the nutraceutical industry. With this solubility advantage, VINIA® also has excellent bioavailability, entering the blood plasma in 20 minutes and providing 12 hours of sustained release. As a result, VINIA® demonstrates a unique ability to support heart health and to improve physical energy and mental alertness, via increased blood flow and delivery of oxygen to the body's tissues and organs.

The successful launch of VINIA® in Israel has provided the Company with experience in the important customer acquisition process and provides confidence in a successful launch of the product in the United States market.

The launch will encompass an integrated marketing mix that leverages the power of a consistent communication message across all major social platforms, including Facebook, YouTube, Google search and other online channels such as Taboola. Significant budget has been allocated to drive awareness amongst consumers aged 40+ regarding the uniqueness of VINIA® and the health and wellness benefits it delivers. In addition, the Company plans to launch an extensive public relations campaign that targets our market demographics.

The first phase of the launch will focus on the science-based credentials of the brand, communicate its superiority over other supplements and emphasize its ability to deliver on multiple wellness benefits. The Company will lead the narrative and will use VINIA® to help educate US consumers in the $53-billion dietary supplement market on the importance of validating the solubility, bioavailability, and efficacy of the supplements they purchase. The Company intends to establish VINIA® as the Gold Standard in the nutraceuticals market.

"This major event is the culmination of over 12 years of extensive R&D", said Dr. Yochi Hagay, CTO of BioHarvest and added "it is the realization of our vision to bring science-based nutraceuticals, with clinically proven benefits, to consumers. Today is validation of the efforts of the R&D team that has relentlessly pursued the development of the BioFarming technology and VINIA®. Most of the team have been with the Company for 12 years and are not only celebrating the culmination of their efforts in such a momentous event but are actively applying the BioFarming platform to the development of new products, including new cannabis-based products".

"I have envisioned this exciting moment ever since I learned about BioHarvest 18 months ago," said Ilan Sobel, CEO of BioHarvest. "I initially became an investor in the Company when I realized the potential of the BioFarming technology platform. When I took the CEO helm nearly a year ago, I focused the efforts and resources of the Company on building a commercial platform and manufacturing capabilities in order to bring the BioFarming based products to the market in an efficient and ultimately profitable way. We initially launched our products in Israel, so that we could test our capabilities. The success we are experiencing in Israel can be a predictor for the US market. I am optimistic about the sales of VINIA® in the US and intend to provide revenue guidance by mid-July 2021."

For more information, consumers and investors are invited to visit vinia.com or call toll free at 1.888.882.2023.

About BioHarvest Sciences Inc.

Based in Vancouver BC, BioHarvest Sciences Inc. is the developer and exclusive owner of the proprietary and patent-protected BioFarming technology. It is the first and only industrial-scale plant cell technology capable of producing the active plant ingredients without the necessity to grow the plant itself. The Company's technology is non-GMO and has already been validated by VINIA®, the red grapes cells functional food/dietary supplement produced and sold by BioHarvest Sciences Inc. The Company plans to generate significant revenue within the global nutraceutical ingredients and dietary supplements market with VINIA® and other Super Fruit Nutraceutical products. Further, by adapting this technology to the Cannabis plant, and building adequate production capacity, BioHarvest Sciences Inc.'s objective is to become a leading supplier of Cannabis for both medicinal and legal recreational purposes. Visit: www.bioharvest.com.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622-1186
Email: dave@bioharvest.com

Twitter
Facebook
LinkedIn
YouTube

Forward-Looking Statements

Information set forth in this news release includes forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Sales are dependent on market acceptance which is subject to consumer preferences that are constantly changing. There is no assurance that the Israeli market results will translate directly into US markets which may depend on different consumer preferences and more substantial marketing expenditures and resources. They can be no assurance that the launch of Vinia® will disrupt the US market. Projected sales of Cannabis will require the company to obtain production and/or export licensing which cannot be assured.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83741

News Provided by Newsfile via QuoteMedia

BioHarvest Sciences

BioHarvest Sciences


Keep reading...Show less
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 P.M. EDT

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of cannabidiol as an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases ("CVD"), is pleased to announce that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on June 28, 2022, at 4:30 p.m. EDT.

Cardiol Therapeutics 2022 AGM

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Gilead Endorses The Kigali Declaration On Preventing, Controlling and Eliminating Neglected Tropical Diseases

- By signing the Kigali Declaration, Gilead joins the global community committed to ending neglected tropical diseases by 2030 -

Gilead Sciences today announced that the company has signed onto the Kigali Declaration on neglected tropical diseases (NTDs) which succeeds the London Declaration on NTDs. It was launched on the margins of the Commonwealth Heads of Government Meeting (CHOGM), at a high-level session that was attended by Heads of State, other global dignitaries, industry partners and global community as part of a joint malaria and NTDs Summit. This high-level political declaration is an important milestone for the World Health Organization's 2030 road map which includes global targets to prevent, control and in some cases eliminate 20 diseases and disease groups by 2030.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities

AbbVie's Week of Possibilities returns in 2022 for its seventh year with approximately 15,000 employees participating in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact Week of Possibilities is AbbVie's global, in-person volunteering program that unites employees around the world with a single purpose: to give back to local communities through volunteering

NORTH CHICAGO, Ill. , June 27, 2022 /PRNewswire/ -- AbbVie kicks off its seventh Week of Possibilities today with approximately 15,000 employees volunteering in more than 50 countries to serve local communities around the world. From June 27 to July 1 , AbbVie employees will work with trusted community partners to complete hands-on projects, including renovating schools, playgrounds and community centers, to benefit local communities impacting tens of thousands of people.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the position of Senior Vice President, Chief Financial Officer (CFO). In this role, Mr. Payne will lead Aptose's financial operations and serve as a member of the Company's executive management team.

"As a highly accomplished CFO, Fletcher brings to Aptose extensive experience in corporate finance, strategy and operations within the biotechnology industry, including the equity capital markets, banking practices and financial transaction experience," said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer. "We are delighted to have him join our executive management team and will benefit from his leadership, strategic insights, and guidance as we advance HM43239 and luxeptinib through clinical development toward commercialization."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

CHMP Recommends Approval of Upadacitinib for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

  • CHMP positive opinion is based on results from the Phase 3 SELECT-AXIS 2 study showing upadacitinib (RINVOQ ® ) met the primary endpoint of ASAS40 response at week 14 versus placebo 1
  • Non-radiographic axial spondyloarthritis (nr-axSpA) is part of the axial spondyloarthritis (axSpA) spectrum and causes inflammation in the spine, leading to back pain and stiffness 2,3,4
  • The EC decision is expected in the third quarter of 2022

ABBVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of upadacitinib (RINVOQ ® 15 mg, once daily) for the treatment of active non-radiographic axial spondyloarthritis (nr‑axSpA) in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) andor magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).*

"Patients with axSpA often experience delayed diagnosis and once they do receive a diagnosis, there are limited therapies available to help control disease symptoms, such as inflammation, back pain and stiffness," said Neil Gallagher , M.D., Ph.D., vice president, development, chief medical officer, AbbVie. "The CHMP's recommendation to approve upadacitinib for patients with nr-axSpA is an important milestone in providing a new treatment option to patients in need."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

U.S. FDA Approves Bristol Myers Squibb's CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy

I n the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile

Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR T cell therapy in patients with primary refractory or relapsed LBCL who are not considered candidates for transplant, in which Breyanzi delivered deep and durable responses

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×